Novartis blood cancer drug wins U.S. OK after setback

February 23, 2015 8:30 PM

3 0

Novartis blood cancer drug wins U.S. OK after setback

(Reuters) - The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval.

The drug, Farydak, in clinical trials almost doubled to 10.6 months the amount of time it took for the disease to progress, compared with standard treatment. But it was associated with a wide array of serious side effects, including severe diarrhea and heart problems, which are prominently listed in...

Read more

To category page

Loading...